| abstract |
Disclosed herein is a pharmaceutical combination comprising at least one thrombin receptor antagonist and at least one cardiovascular agent. Examples of cardiovascular agents suitable for co-formulation or administration with a thrombin receptor antagonist include endothelin antagonists selected from the group consisting of tezosentan, bosentan, and sitaxsentan. In one embodiment, the invention includes a method of treating or preventing a cardiovascular condition in a mammal in need of treatment of the cardiovascular condition, the method comprising a first pharmaceutical composition comprising a thrombin receptor antagonist. And a second pharmaceutical composition comprising a cardiovascular agent is administered to the mammal. |